参考文献/References:
[1]Desai S, Zhu MJ, LapidosSalaiz I. Cervical cancer prevention: Human papillomavirus testing as primary screening. Cancer,2022,128(5):939-943.
[2]张仲华,刘晨瑛, 任会叶,等.2003-2018 年间中国女性宫颈癌发病与死亡趋势研究.中华疾病控制杂志,2022,26(1):14-20.
[3]Wright JD, Matsuo K, Huang YM, et al. Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines. Obstet Gynecol,2019,134(1):49-57.
[4]Carbone A, Borok M, Damania B, et al. Castleman disease. Nat Rev Dis Primers,2021,7(1):84.
[5]Midori FN, Yoshito N, Asami N, et al. Historical and pathological overview of Castleman disease. J Clin Exp Hematop,2022,62(2):60-72.
[6]Pria AD, Pinato D, Roe J, et al. Relapse of HHV8positive multicentric Castleman disease following rituximabbased therapy in HIVpositive patients. Blood,2017,129(15):2143-2147.
[7]Eaton C, Dorer R, Aboulafia DM. Human herpesvirus8 infection associated with kaposi sarcoma, multicentric Castleman’s disease, and plasmablastic microlymphoma in a man with AIDS: A case report with review of pathophysiologic processes. Patholog Res Int,2010,2011:647518.
[8]Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood,2020,135 (16):1353-1364.
[9]Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol,2018,180(2):206-216.
[10]张清许,宋志国,王伟,等.肾上腺Castleman病一例报告.中华泌尿外科杂志,2021,42(10):780-781.
[11]Cronin DMP, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol,2009,16(4):236-246.
[12]东洁,徐维锋,周敬敏,等.腹膜后Castleman病13例报告并文献复习.中国微创外科杂志,2018,18(9):787-791．
[13]Boutboul D, Fadlallah J. Chawki S, et al. Treatment and outcome of unicentric castleman disease: A retrospective analysis of 71 cases. Br J Haematol,2019,186 (2):269-273.
[14]Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood,2018,132(22):2323-2330.